618 results on '"Bruse S"'
Search Results
2. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
3. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
4. Defizienz der homologen Rekombinationsreparatur als prädiktiver Marker: Grundlagen und Nachweis
5. Bewertung des miR371a-Tests bei Patienten, die sich einer inguinalen Orchidektomie oder Enukleation bei Verdacht auf Hodentumor unterziehen
6. Status der Verfügbarkeit und Anwendung von „next generation sequencing“ (NGS) beim Harnblasenkarzinom – eine Umfrage in der Arbeitsgemeinschaft Uropathologie
7. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
8. Detektion und Interpretation somatischer Varianten in der Molekularpathologie
9. KEAP1/NFE2L2 pathway signature outperforms KEAP1/NFE2L2 mutation status and reveals alternative pathway-activating mutations in Non-Small Cell Lung Cancer
10. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
11. Evaluation of miRNA-371a-3p (miR371a) assay to predict final pathohistology in patients undergoing primary nerve-sparing retroperitoneal lymphadenectomy (nsRPLND) for stage IIA/B seminomas and non-seminomas
12. Reference standards for gene fusion molecular assays on cytological samples: an international validation study
13. ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology
14. 9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential
15. Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel
16. Bericht über die Sitzungen und die Mitgliederversammlung der AG Molekularpathologie
17. EP08.02-031 NRF2 Pathway Signature Predicts KEAP1/NFE2L2 Mutations and Reveals Alternative Pathway-Activating Mutations in NSCLC
18. EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients
19. 572P High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer
20. EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations
21. 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
22. 1729P The biological effect of small-scale ROS1 aberrations: An in silico analysis
23. 1308P Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations
24. EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
25. ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics
26. The biological effect of small-scale ROS1 aberrations: An in silico analysis
27. Small-scale ROS1 aberrations: Functional impact and therapeutic potential
28. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM)
29. High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer
30. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
31. 52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics
32. Internal Fixation of Fresh Fractures
33. Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies
34. 758P Concordance between multiple HRD assays is substantial in high-grade ovarian cancer
35. Prevalence and potential biological role of TERT amplifications in ALK translocated adenocarcinoma of the lung.
36. Concordance between multiple HRD assays is substantial in high-grade ovarian cancer
37. Homologous recombination repair deficiency as a predictive biomarker Basic mechanisms and detection methods
38. Multi-center real-world comparison of the fully automated Idylla™ microsatellite instability assay with routine molecular methods and immunohistochemistry on formalin-fixed paraffin-embedded tissue of colorectal cancer
39. BRAF-Mutationstestung beim metastasierten malignen Melanom
40. 1383P Efficacy of capmatinib compared to standard of care for German patients with locally advanced or metastatic NSCLC harboring METex14 mutations: Results from the RECAP study
41. 1374P Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
42. 1329P FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
43. Brauchen wir in Deutschland Sarkomzentren?: Erfahrungen aus dem Bonner GIST-Register
44. Molekulare Methoden in der Sarkomdiagnostik
45. Gastrointestinale Stromatumoren des Magens: Neues und Besonderes im Vergleich zu anderen Lokalisationen
46. Inflammatorischer fibroider Polyp: Von Vaněks „submukösem Granulom“ zum Konzept einer submukösen mesenchymalen Neoplasie
47. Pathologie und Molekularbiologie gastrointestinaler Stromatumoren (GIST)
48. Inflammatorische fibroide Polypen sind echte Neoplasien mit PDGFRA-Mutationen
49. The Network Genomic Medicine: A prospective comprehensive molecular screening network for implementation of personalized lung cancer therapy: ID 376
50. A retrospective analysis of overall survival of ALK translocation - and of EGFR mutation positive NSCLC patients treated with and without personalized therapy: ID 381
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.